Frontlight ResearchEarly access
WithdrawnNo phase
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Key facts
- Who runs it
- Hebei Medical University Fourth Hospital
- Trial code
- Status
- Withdrawn
- Started
- 30 May 2024
- Expected to end
- 30 May 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Adebrelimab+TP/FP+ radiation therapy
- Adebrelimab+FP/TP+ radiation therapy
- Record updated
- 26 August 2025
- Why it stopped
- The primary reason for termination was difficulty in recruitment
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- 1.Age 18-75 years old, both men and women; 2.Histopathology confirmed as esophageal squamous cell carcinoma,stage II-IVa:T1N2-3M0,T2-4bN+M0; 3.If technically feasible, all patients are recommended to have local staging determined by endoscopic ultrasound (EUS); The endoscopic examination report or gastrointestinal (GI) clinical records should clearly indicate the T and N stages; Perform PET-CT examination; 4.Except for basal or squamous cell skin cancer, bladder cancer in situ or cervical cancer, there is no history of malignant tumor within 5 years; Patients with malignant tumors who have undergone surgical treatment in the past and those who have survived disease-free for more than 5 years meet the inclusion criteria; 5.Have not received any systemic anti-tumor treatment in the past (systemic chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) 6.According to RECIST 1.1, at least one measurable lesion; 7.ECOG: 0~1; 8.Expected survival period ≥ 12 weeks; 9.Major organ function has to meet the following certeria:
- Blood routine examination:; HB≥90g/L; ANC ≥ 1.5 × 109 / L; PLT ≥ 100 × 109 / L
- Biochemical examination:; ALT and AST < 2.5×ULN; TBIL ≤ 1.5×ULN; Cr ≤ 1.5×ULN; 9. Left ventricular ejection fraction (LVEF) ≥50%; 11. Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; negative serum or urine pregnancy test within 7 days prior to study enrollment And must be non-lactating patients; males should agree to patients who must use contraception during the study period and within 6 months after the end of the study period; 12. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up
Who cannot take part
- Previous history of esophageal cancer surgery;
- Received systemic immunosuppressive therapy within 14 days prior to the first study medication;
- Severe infections within 4 weeks before study drug administration, or active infection with CTCAE ≥ 2 grade treated with antibiotics within 2 weeks before study drug administration
- Higher risk of esophageal perforation or fistula;
- Known or suspected to have interstitial pneumonia; Other moderate to severe lung diseases that may seriously affect respiratory function
- The patient has any active autoimmune disease or history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, enteritis, systemic lupus erythematosus, rheumatoid arthritis; patients with vitiligo, Asthma has been completely relieved in childhood, and patients who do not need any intervention after adulthood can be included; asthma patients who require bronchodilators for medical intervention cannot be included)
- Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥ 1000 copies/ml or 500IU/ml), hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of detection of the analytical method);
- History of cardiovascular disease with significant clinical significance, including but not limited to: (1) congestive heart failure (NYHA grade>2); (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within 3 months; (4) Any supraventricular arrhythmias or ventricular arrhythmias that require treatment or intervention
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
- History of psychiatric drugs abuse and can't quit or patients with mental disorders
- Within 6 months, cerebral vascular accidents (including transient ischemic attacks or symptomatic pulmonary embolism) occur
- The researchers think inappropriate
What happens in this trial
What the trial wants to find out
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.
The 2 groups in the trial
- PET-CT respondersTreatment being tested
SUV (PETr) reduction \>35%
Treatment: Adebrelimab+TP/FP+ radiation therapy
- PET-CT non-respondersTreatment being tested
SUV (PETr) reduction ≤35%
Treatment: Adebrelimab+FP/TP+ radiation therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC): A Prospective, Single-arm, Phase II Clinical Study
- Record updated
- 26 August 2025